Entering text into the input field will update the search result below

Aeterna Zentaris inks Zoptrex license deal in Asia; shares ahead 10% premarket

  • Thinly traded nano cap Aeterna Zentaris (NASDAQ:AEZS) is up 10% premarket on light volume in response to its announcement that it has signed a license agreement with Cyntec Co., Ltd., for lead anti-cancer candidate Zoptrex (zoptarelin doxorubicin). The agreement covers Taiwan and nine countries in Southeast Asia. The initial indication will be endometrial cancer.
  • Under the terms of the deal, AEZS will receive an undisclosed upfront payment, milestones and royalties on net sales. Cyntec will be responsible for the development, registration, reimbursement and commercialization of Zoptrex in the territory.
  • Zoptrex combines a synthetic peptide carrier with the chemo agent doxorubicin. The carrier, a modified natural hormone with a strong affinity for the LHRH (luteinizing hormone-releasing hormone) receptor, enables the selective delivery of the chemo agent to LHRH receptor-positive tumors.

Recommended For You

Related Stocks

SymbolLast Price% Chg
AEZS
--
AEZS:CA
--
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.